Relationship between disease-modifying therapy and depression in multiple sclerosis

International Journal of MS Care

Volumn 15, Issue 3, 2013, Pages 107-112

  Kirzinger, Stephen S ^a   Jones, Jason ^b   Siegwald, Angela ^a   Crush, Andrew Bryce ^a  

^a University of Louisville School of Medicine   (United States)

^b INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888365545     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2012-036     Document Type: Article

References (30)

1. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76:469-475.
2. Caine ED, Schwid SR. Multiple sclerosis, depression, and the risk of suicide. Neurology. 2002;59:662-663.
3. Patten SB, Williams JV, Metz LM. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler. 2008;14:406-411.
4. Jose SM. Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg. 2008;110:868-877.
5. Wallin MT, Wilken JA, Turner AP, Williams RM, Kane R. Depression and multiple sclerosis: review of a lethal combination. J Rehabil Res Dev. 2006;43:45-62.
6. Patten SB, Metz LM. Depression in multiple sclerosis. Psychother Psychosom. 1997;66:286-292.
7. Ehde DM, Bombardier CH. Depression in persons with multiple sclerosis. Phys Med Rehabil Clin N Am. 2005;16:437-448, ix.
8. Avonex [prescribing information]. Cambridge, MA: Biogen Idec Inc; 2012.
9. Rebif [prescribing information]. New York, NY: Pfizer Inc; 2011.
10. Betaseron [prescribing information]. Montville, NJ: Bayer HealthCare Pharmaceuticals Inc; 2010.
11. Arnett PA, Randolph JJ. Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77:606-610.
12. Goeb JL, Cailleau A, Laine P, et al. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 2003;26:5-7.
13. Pandya R, Patten S. Depression in multiple sclerosis associated with interferon beta-1a (Rebif). Can J Psychiatry. 2002;47:686.
14. Udina M, Castellví P, Moreno-Espana J, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012;73:1128-1138.
15. Dutcher JP, Logan T, Gordon M, et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a Cytokine Working Group study. Clin Cancer Res. 2000;6:3442-3450.
16. Wilken JA, Sullivan C. Recognizing and treating common psychiatric disorders in multiple sclerosis. Neurologist. 2007;13:343-354.
17. R Development Core Team. R: a language and environment for statistical computing. 2012.
18. Patten SB, Fridhandler S, Beck CA, Metz LM. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler. 2003;9:616-620.
19. Patten SB, Metz LM. Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology. 2002;59:744-746.
20. Feinstein A. Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler. 2000;6: 343-348.
21. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889-897.
22. Schippling S. Impact of depression in multiple sclerosis during treatment with interferon beta-1b and glatiramer acetate in the multinational BEYOND study [abstract]. Mult Scler. 2009;15(suppl):S118.
23. PRISMS Study Group and the University of British Columbia MS/MRI Analyses Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628-1636.
24. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
25. Lynch SG, Kroencke DC, Denney DR. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope. Mult Scler. 2001;7:411-416.
26. Hart S, Fonareva I, Merluzzi N, Mohr DC. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res. 2005;14: 695-703.
27. Lester K, Stepleman L, Hughes M. The association of illness severity, self-reported cognitive impairment, and perceived illness management with depression and anxiety in a multiple sclerosis clinic population. J Behav Med. 2007;30:177-186.
28. Mohr DC, Hart SL, Fonareva I, Tasch ES. Treatment of depression for patients with multiple sclerosis in neurology clinics. Mult Scler. 2006;12:204-208.
29. Sollom AC, Kneebone II. Treatment of depression in people who have multiple sclerosis. Mult Scler. 2007;13:632-635.
30. Walker ID, Gonzalez EW. Review of intervention studies on depression in persons with multiple sclerosis. Issues Ment Health Nurs. 2007;28:511-531.